ArticleUltrasonography (Seoul, Korea)2026
Construction of a nomogram model for predicting benignity and malignancy in adnexal masses.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeThis study aimed to construct a simple nomogram model to predict the benign or malignant nature of ovarian masses.
methodsA total of 794 patients with ovarian masses from two independent medical centers between 2017 and 2024 were included. Among them, 700 patients from center 1 were randomly divided into training and internal validation datasets, and 94 patients from center 2 comprised the external validation dataset. Clinical information, ultrasound images, and sonographic characteristics were collected for all patients. Independent risk factors were screened and incorporated into the nomogram. The diagnostic performance of the nomogram was compared with that of the Risk of Malignancy Index 4 (RMI4) and Ovarian-Adnexal Reporting and Data System (O-RADS) models.
resultsUltrasound score, menopausal status, maximum tumor diameter, elevated carbohydrate antigen 125, and elevated human epididymis protein 4 were identified as independent risk factors for distinguishing benign from malignant ovarian masses. In the training, internal validation, and external validation datasets, the areas under the receiver operating characteristic curve (AUCs) were 0.912, 0.906, and 0.949, respectively. The corresponding sensitivity values were 79.9%, 71.2%, and 93.3%, and the specificity values were 87.6%, 90.4%, and 86.7%, respectively. Compared with RMI4 and O-RADS, the nomogram demonstrated the highest AUC and greater clinical net benefit.
conclusionThe nomogram is simple to apply and demonstrates significantly higher diagnostic performance than RMI4, while achieving comparable performance to O-RADS. It may serve as a practical and widely applicable tool for predicting the benign or malignant nature of ovarian tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.